LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation - P. A. Ascierto, M. Mandala, P. F. Ferrucci, M. Guidoboni, P. Rutkowski, V. Ferraresi, A. M. Arance Fernandez, M. Guida, E. Maiello, H. J. Gogas, E. Richtig, M. T. Fierro, C. Lebbe, H. Helgadottir, I. Melero - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Annals of Oncology, (33), p. S1408-S1409, 2022

DOI: 10.1016/j.annonc.2022.08.040

Links

Tools

Export citation

Search in Google Scholar

LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

Journal article published in 2022 by P. A. Ascierto, M. Mandala, P. F. Ferrucci, M. Guidoboni, P. Rutkowski, V. Ferraresi, A. M. Arance Fernandez, M. Guida, E. Maiello, H. J. Gogas, E. Richtig, M. T. Fierro, C. Lebbe, H. Helgadottir, I. Melero and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO